1. Home
  2. CNXC vs DMRA Comparison

CNXC vs DMRA Comparison

Compare CNXC & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$22.26

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$28.86

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNXC
DMRA
Founded
1991
2011
Country
United States
United States
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CNXC
DMRA
Price
$22.26
$28.86
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$54.80
$43.00
AVG Volume (30 Days)
2.2M
841.0K
Earning Date
03-24-2026
05-11-2026
Dividend Yield
5.79%
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$9,825,771,000.00
N/A
Revenue This Year
$5.29
N/A
Revenue Next Year
$2.49
N/A
P/E Ratio
$18.28
N/A
Revenue Growth
2.15
N/A
52 Week Low
$19.12
$16.50
52 Week High
$60.63
$34.89

Technical Indicators

Market Signals
Indicator
CNXC
DMRA
Relative Strength Index (RSI) 43.78 53.60
Support Level $22.05 $22.71
Resistance Level $25.93 N/A
Average True Range (ATR) 1.58 2.72
MACD -0.02 -0.19
Stochastic Oscillator 36.68 35.35

Price Performance

Historical Comparison
CNXC
DMRA

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: